Hydroxychloroquine, Radiation, and Temozolomide Treating Patients With Newly Diagnosed Glioblastoma Multiforme

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

92

Participants

Timeline

Start Date

October 29, 2007

Primary Completion Date

June 30, 2013

Study Completion Date

January 31, 2014

Conditions
Brain and Central Nervous System Tumors
Interventions
DRUG

hydroxychloroquine

see arm description, the first 10 week cycle is call initiation cycle, Post the 10 week cycle of just HCQ, 4 week cycles are called Maintenance Cycles

DRUG

temozolomide

TMZ daily 75mg/m2 for 6wks with RT+HCQ (TMZ is given only during Initiation cycle)

OTHER

pharmacological study

Seven samples in total will be collected baseline, initiation cycle -week3-4, week9-10, Maintenance Cycle 1 Week 4 (C1W4), Cycle2 Week4, Cycle3 Week4, Cycle6 Week4

RADIATION

Radiation

Radiation during the first six weeks of treatment Monday-Friday

Trial Locations (9)

30322

Winship Cancer Institute of Emory University, Atlanta

35294

University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham

48202

Josephine Ford Cancer Center at Henry Ford Hospital, Detroit

33612-9497

H. Lee Moffitt Cancer Center and Research Institute at University of South Florida, Tampa

21231-2410

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

02114

Massachusetts General Hospital, Boston

27157-1096

Wake Forest University Comprehensive Cancer Center, Winston-Salem

44106-5065

Case Comprehensive Cancer Center, Cleveland

19104-4283

Abramson Cancer Center of the University of Pennsylvania, Philadelphia

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT00486603 - Hydroxychloroquine, Radiation, and Temozolomide Treating Patients With Newly Diagnosed Glioblastoma Multiforme | Biotech Hunter | Biotech Hunter